MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

Written By LINQ management

MinervaXApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful completion of a 72 million EUR financing round. The equity financing of 22 million EUR was co-led by new investors Trill Impact Ventures and Pureos Bioventures and includes existing investors REPAIR Impact Fund (Novo Holdings), Sunstone Life Science Ventures, LF Investment, Wellington Partners, Sanofi Ventures, Adjuvant Capital and Industrifonden. In addition to the equity financing, theEuropean Investment Bankprovided a 50 million EUR loan facility.

Read more here MinervaX.

LINQ management https://www.linq-management.com
Previous

Present your research at the virtual Group B Strep in Pregnancy & Babies 2023 Conference – Wednesday 17 May 2023
Next

ISSAD Conference 2021 – Poster Prize